Research company Cantargia has appointed Dr. Hilde Steineger as its new Chief Executive Officer, effective September 1. Steineger most recently served as co-founder and Chief Operating Officer at NorthSea Therapeutics, as well as CEO of Staten Biotechnology since 2017, where she led a $480 million licensing deal with Novo Nordisk. The announcement was made in a press release.
"We welcome Dr. Hilde Steineger as our new CEO. Her appointment is a natural progression for Cantargia as a maturing company with two product candidates in clinical development and having recently completed a transaction with an international pharmaceutical company," said Chairman Magnus Persson.
Hilde Steineger succeeds interim CEO Damian Marron, who will remain on the board of directors.
"I am very pleased to be joining Cantargia at this exciting stage of its development. The company's focus on innovative antibody-based therapies targeting IL1RAP and its strategic partnership with Otsuka represent significant opportunities to develop effective treatments," commented Hilde Steineger regarding her new role.
